We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A third shot of AstraZeneca’s COVID-19 vaccine used as a booster prompts a strong immune response, including against variant strains of the SARS-CoV-2 virus, Oxford University researchers reported yesterday. Read More
A real-world study of vaccinated individuals who received the Pfizer shot showed that it offered 87.9 percent protection against the Delta variant. Read More
Under the agreement, Horizon will have a worldwide exclusive license to the therapeutic and will be wholly responsible for clinical development and commercialization. Read More
Sponsors developing drugs to treat breast cancer should consider including premenopausal women in their clinical trials and may be required to conduct postmarketing studies to analyze the long-term effects of these treatments, the FDA said in a final guidance. Read More
Gilead Sciences has said its antiviral Veklury (remdesivir) reduced hospitalization and death rates for COVID-19 patients, based on new results from three real-world studies. Read More
Horizon Therapeutics has entered into a $700 million development and licensing deal with Arrowhead Pharmaceuticals for Arrowhead’s investigational RNA interference (RNAi) treatment for gout. Read More
GlaxoSmithKline (GSK) and Vir Biotechnology have reported that final results from their phase 3 study on sotrovimab show that the monoclonal antibody — which was granted Emergency Use Authorization (EUA) by the FDA on May 27 — significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease. Read More
Lupus, which affects multiple organs and is linked with a greater risk of death from infection and heart disease, among other conditions, afflicts an estimated 4 million individuals worldwide. Read More
Biogen has launched a phase 3 trial of its monoclonal antibody, BIIB059, a potential blockbuster that has shown promise for treating individuals suffering from lupus, a chronic and debilitating autoimmune disease. Read More
Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz (tofacitinib) reduced the incidence of death or respiratory failure among hospitalized patients with COVID-19 pneumonia in a Brazilian study. Read More